Imunon, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsImunon is a clinical-stage biotechnology company developing a non-viral DNA immunotherapy platform, with its lead candidate IMNN-001 in Phase 3 testing for advanced ovarian cancer.
What they do
Imunon uses its non-viral DNA delivery technology across two modalities: TheraPlas, for encoding proteins and cytokines to treat solid tumors, and PlaCCine, for encoding viral antigens for vaccines. The lead program, IMNN-001, is a DNA-based immunotherapy that instructs the body to produce interleukin-12 and interferon gamma at the tumor site, being developed for advanced ovarian cancer. The company has also completed a first-in-human study of its COVID-19 booster vaccine, IMNN-101.
Revenue drivers
- Product sales — No revenue from product sales is expected in the next several years; the company is pre-commercial.
- Collaborations and partnerships — The company may enter collaborative arrangements to complete development and commercialization, but none are currently generating revenue.
- Grants and subsidies — May apply for government or agency-sponsored funding to reduce development costs, but no such awards are currently reported.
Recent performance
For the second quarter of 2026, Imunon reported financial results but specific quarterly figures were not provided in the excerpt. Annual net loss was $18.6 million in 2024, $19.5 million in 2023, and $35.9 million in 2022. Diluted EPS was -$16.94 in 2024, -$2.16 in 2023, and -$5.03 in 2022. Operating cash flow was -$18.9 million in 2024 and -$13.9 million in 2025.
Strategy
Imunon's strategy is to advance its non-viral DNA technology across multiple modalities, focusing on IMNN-001 for ovarian cancer. The company plans to complete the Phase 3 OVATION 3 trial and leverage its platform for other indications, including vaccines. It may also evaluate licensing products from third parties and pursue strategic alternatives, including collaborations or acquisitions.
Risks
- Clinical trial failure — IMNN-001 is in Phase 3; the outcome of OVATION 3 is uncertain and could materially affect the company's prospects.
- No revenue and going concern — The company expects no product revenue for several years and has sustained significant net losses since inception.
- Financing risk — The company raised $10 million in June 2026 via preferred stock and secured notes, but may need additional capital to fund operations.
- Regulatory and competitive risk — The company operates in a highly regulated, competitive environment; delays or failures in FDA approvals could harm the business.
Outlook
Management expects to complete enrollment in the Phase 3 OVATION 3 trial by the first half of 2029, supported by Phase 2 data showing an overall survival benefit. The independent Data Monitoring Committee recommended continuation of OVATION 3 in June 2026. The company also plans to host an R&D Day on September 2, 2026.